Four designated centres, KAMC, KFSH&RC, Sidra Medicine, and SKMC, carry nearly all GCC SMA gene-therapy and specialist referral activity, evidence of how concentrated regional SMA expertise actually is.
GCC spinal muscular atrophy specialist care runs through a small set of tertiary paediatric neurology centres rather than a broad national footprint. Newborn-screening-identified pre-symptomatic infants are treated at King Abdulaziz Medical City (KAMC), King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Sidra Medicine in Doha, and Sheikh Khalifa Medical City (SKMC) in Abu Dhabi. KFSH&RC carries additional weight as the GCC's sole SFDA-authorised gene-therapy administration centre, where roughly 80 to 100 children treated with Zolgensma since 2020 are now four to seven years old and under six-monthly HFMSE/RULM motor-function monitoring, the region's only structured attenuation-cohort follow-up programme. Our KOL Universe gate (K1) starts by mapping this four-centre concentration before any single physician is scored.
That structure changes how AXLRx tiers scientific and commercial influence across the GCC. A physician at KFSH&RC overseeing gene-therapy administration and attenuation-cohort follow-up carries different scientific weight than one at a centre without SFDA gene-therapy authorisation, and our Tier Classification gate (K2) scores that distinction directly, alongside SMN1/SMN2 genetic-testing capability and NPHC/MOH guideline-submission roles. That same concentration also shapes the Type 4 adult-onset misdiagnosis problem: an estimated 50 to 150 undiagnosed GCC adults are currently classified as ALS or limb-girdle muscular dystrophy where genetic testing is not routinely ordered outside these four centres, making testing capability at each site a direct KOL-tiering input rather than a background fact. No named individual enters the workbook without a verification tag, checked against live publication and institutional-affiliation records, then marked Verified, Industry benchmark, or Requires client validation.
The GCC SMA centre network — four designated institutions, one gene-therapy site
| Institution | Country / City | Role in SMA Pathway |
|---|---|---|
| King Abdulaziz Medical City (KAMC) | Saudi Arabia (Riyadh) | Newborn-screening-identified pre-symptomatic infant care |
| King Faisal Specialist Hospital and Research Centre (KFSH&RC) | Saudi Arabia (Riyadh) | Sole SFDA-authorised gene-therapy administration centre; Zolgensma-attenuation cohort follow-up |
| Sidra Medicine | Qatar (Doha) | Newborn-screening-identified pre-symptomatic infant care; paediatric neurology referral |
| Sheikh Khalifa Medical City (SKMC) | UAE (Abu Dhabi) | Newborn-screening-identified pre-symptomatic infant care; paediatric neurology referral |
Sources: Al-Jasmi F et al., Orphanet J Rare Dis 2016; Saudi National Newborn Screening Programme 2022-2023; NPHC SMA coverage decision documentation; KFSH&RC gene therapy programme SMA outcomes.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The four-centre GCC structure (KAMC, KFSH&RC, Sidra Medicine, SKMC)
- institutional concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- gene-therapy authorisation and SMN1/SMN2 genetic-testing capability as weighting inputs
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the four-centre GCC structure before the rest of the workbook is built out
- Every GCC SMA KOL sized and sourced from institutional-affiliation and gene-therapy-authorisation data
- KAMC, KFSH&RC, Sidra Medicine, and SKMC as the sizing anchor
- Universe boundaries: who counts as a KOL versus a general paediatric referrer
- Scientific-influence scoring across gene-therapy authorisation, attenuation-cohort follow-up, and SMN1/SMN2 genetic-testing capability
- What separates a Tier 1 KOL from a general community paediatrician
- Influence inputs: gene-therapy administration role, attenuation-cohort data ownership, NPHC/MOH guideline involvement
- Cross-checked against independent publication and institutional data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Riyadh, Doha, and Abu Dhabi, and the rest of the GCC
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond their home country, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live institutional-affiliation, gene-therapy-authorisation, and payer-coverage documentation, not secondary summaries. No KOL name ships without a verification tag.
GCC SMA KOL sources: Al-Jasmi F et al., Orphanet J Rare Dis 2016; Saudi National Newborn Screening Programme 2022-2023; NPHC SMA coverage decision documentation; and the KFSH&RC gene therapy programme SMA outcomes reporting.
- Four-centre GCC structure verified against Al-Jasmi F et al., Orphanet J Rare Dis 2016 and NPHC SMA coverage decision documentation
- KFSH&RC sole-authorisation status and attenuation-cohort size verified against KFSH&RC gene therapy programme SMA outcomes reporting
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC spinal muscular atrophy specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.